Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing novel treatments for cancer and its life-threatening complications.
Cantex’s pipeline consists of three product candidates – Azeliragon, Dicopp® and DSTAT. These drugs are in clinical development for cancers for which innovative and more effective treatments are greatly needed.
Azeliragon is an orally administered small molecule, taken once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins produced by cancer cells. Azeliragon was under development by the company from which we licensed the compound for Alzheimer’s disease and failed to show efficacy in phase 3 trials. Clinical safety data from these trials, with over 1500 individuals dosed for periods up to 18 months, indicates that azeliragon is very well tolerated. Cantex is planning clinical trials of azeliragon as a potential treatment of life-threatening complications of pancreatic cancer and breast cancer.
Dicopp®, which is a proprietary combination of disulfiram + copper, is being developed for the treatment of hematologic malignancies. A Phase 1/2 study of Dicopp® as a treatment of relapsed/refractory myeloma is in progress and a Phase 2 study in refractory myelodysplastic syndrome is planned.
DSTAT, licensed to Chimerix in July 2019, is being studied in a Phase 3 study that is in progress in acute myeloid leukemia (AML). Cantex remains involved in the continued development of DSTAT via a Joint Development Committee. A randomized Phase 2 clinical trial in AML indicated that DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity. As noted in the discussion of our pipeline, Cantex will derive milestones and royalties from the future success of this product.